Acupuncture for dysphagia after chemoradiation in head and neck cancer: rationale and design of a randomized, sham-controlled trial.
Contemp Clin Trials., Jul;33(4):700-11 (2012)
The neutralization properties of a HIV-specific antibody are markedly altered by glycosylation events outside the antigen-binding domain.
J. Immunol., Jun;178(11):7132-8 (2007)
A bispecific antibody composed of a nonneutralizing antibody to the gp41 immunodominant region and an anti-CD89 antibody directs broad human immunodeficiency virus destruction by neutrophils.
J. Virol., May;82(9):4671-4 (2008)
Dichotomy in cross-clade reactivity and neutralization by HIV-1 sera: Implications for active and passive immunotherapy.
J. Med. Virol., Jun;76(2):146-52 (2005)
CD40 function in squamous cell cancer of the head and neck.
Oral Oncol., May;41(5):462-9 (2005)
Evidence of determinant spreading in the antibody responses to prostate cell surface antigens in patients immunized with prostate-specific antigen.
Clin. Cancer Res., Feb;8(2):368-73 (2002)
A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck.
Cancer., Oct;95(7):1472-81 (2002)
Interactions of human antibodies, epitope exposure, antibody binding and neutralization of primary isolate HIV-1 virions.
AIDS., Dec;16(18):2409-17 (2002)
Binding and neutralization activity of human IgG1 and IgG3 from serum of HIV-infected individuals.
AIDS Res. Hum. Retroviruses., Sep;19(9):785-92 (2003)
A human anti-HIV autoantibody enhances EBV transformation and HIV infection.
Clin. Immunol., Dec;93(3):263-73 (1999)
Serum concentrations of interleukin-8, vascular endothelial growth factor, and epidermal growth factor receptor in patients with squamous cell cancer of the head and neck.
Oral Oncol., Jan;41(1):70-6 (2005)
Effect of antibody valency on interaction with cell-surface expressed HIV-1 and viral neutralization.
J. Immunol., Mar;152(5):2538-45 (1994)
Plasma pharmacokinetics and biological activity of a human immunodeficiency virus type 1 neutralizing human monoclonal antibody, F105, in cynomolgus monkeys.
J Immunother Emphasis Tumor Immunol., May;15(4):251-6 (1994)
Influence of heavy chain constant regions on antigen binding and HIV-1 neutralization by a human monoclonal antibody.
J. Immunol., Oct;155(7):3638-44 (1995)
Phase I study of a human monoclonal antibody directed against the CD4-binding site of HIV type 1 glycoprotein 120.
AIDS Res. Hum. Retroviruses., May;14(7):545-50 (1998)
Functional and molecular characterization of human monoclonal antibody reactive with the immunodominant region of HIV type 1 glycoprotein 41.
AIDS Res. Hum. Retroviruses., Sep;14(14):1271-80 (1998)
Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for squamous cell carcinoma of the head and neck: long-term results.
J. Clin. Oncol., Sep;15(9):3100-10 (1997)
Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120.
J. Acquir. Immune Defic. Syndr., Jan;6(1):7-14 (1993)
Integrating systemic agents into multimodality treatment of locally advanced head and neck cancer.
Ann. Oncol., Oct;21 Suppl 7:vii246-51 (2010)
Induction chemotherapy in locally advanced head and neck cancer: a new standard of care?
Hematol. Oncol. Clin. North Am., Dec;22(6):1155-63, viii (2008)